23andMe's Fatal Flaw | Defying Gravity? | 2

23andMe's Fatal Flaw | Defying Gravity? | 2

Up next

23andMe's Fatal Flaw | Guess Who’s Back | 3

Just when it looked like 23andMe was selling to Regeneron Pharmaceuticals, founder Anne Wojcicki placed a bid through her new nonprofit in an attempt to win it back at the eleventh hour. Lila MacLellan, Senior Writer at Fortune, joins David to discuss Wojcicki’s leadership style, ...  Show more

Rebuilding LEGO | A Burning Platform | 1

It’s early 1997, and after decades of success, LEGO is rocked by a sudden collapse in its profit. To recover, the Danish toy manufacturer jacks up its innovation efforts. But can it deliver a company-saving idea in time?Be the first to know about Wondery’s newest podcasts, curate ...  Show more

Recommended Episodes

Extra: Why Is 23andMe Going Under? (Update)
Freakonomics Radio

Five years ago, we published an episode about the boom in home DNA testing kits, focusing on the high-flying firm 23andMe and its C.E.O. Anne Wojcicki. Their flight has been extremely bumpy since then. This update includes an additional interview with the Wall Street Journa ...

  Show more

How 23andMe went from a $6 billion valuation to trading for pennies
World Changing Ideas

Cofounder and CEO of 23andMe, Anne Wojcicki, wants to take the public company private. Founded in 2006, the DNA-testing startup was valued at $6 billion in 2021. Now, it’s trading for less than a dollar. So what happened? ‘Fast Company’ senior writer Ainsley Harris breaks down 23 ...  Show more

CEO Series: 23andMe’s Anne Wojcicki on Scientific Breakthroughs and Public Trust
HBR IdeaCast

Anne Wojcicki, CEO of 23andMe, spent a decade in healthcare and biotechnology before launching the DNA testing and analysis company in 2006. Her goal was twofold: to help individuals learn more about their own genetics, enabling them to pursue more personalized medical care, and ...  Show more

The rise and fall of DNA testing company 23andMe
Science Weekly

The genetic testing firm 23andMe has filed for bankruptcy, another twist in the story of a company that promised a pioneering approach to precision health. Now users are scrambling to delete their personal data, with the future ownership of the firm uncertain. To understand the h ...  Show more